A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression.
becks depression inventory and ham-d scales
depression
desvenlafaxine
dsm-v criteria
sertraline
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
accepted:
28
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Background Depression is one of the most predominant mental health issues that are prevalent now. Therefore, many clinical trials were being conducted to find the safest, most effective, and tolerable anti-depressant. This study aims to compare desvenlafaxine and sertraline regarding their safety and efficacy in treating depression. Methodology The patients who were diagnosed with depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria were included in the study and were divided into two groups. The severity of depression in these patients was evaluated using Beck Depression Inventory and Hamilton depression scale (HAM-D) before and after the treatment (four weeks). Results About 64% of the study sample were males, and 36% were females, with 77% of the patients in the desvenlafaxine group taking 100 mg dosage and about 74% patients taking 50 mg dosage in the sertraline group. The patients in both groups showed statistically significant (p < 0.00001) improvement after using these drugs. Conclusion Both desvenlafaxine and sertraline showed their efficacy in treating depression by improving the clinical outcome in patients. Sertraline was marginally better in clinical results. Finally, it is advisable to carry out more randomized trials to improve the patient's quality of life.
Identifiants
pubmed: 35371643
doi: 10.7759/cureus.22717
pmc: PMC8971119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e22717Informations de copyright
Copyright © 2022, Ch et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 1998 Nov 18;280(19):1665-72
pubmed: 9831997
JAMA. 1989 Aug 18;262(7):914-9
pubmed: 2754791
Curr Med Res Opin. 2008 Jul;24(7):1877-90
pubmed: 18507895
Cureus. 2021 Nov 30;13(11):e20032
pubmed: 34987917
J Psychopharmacol. 2000 Mar;14(1):3-20
pubmed: 10757248
J Psychiatry Neurosci. 2002 Jul;27(4):250-7
pubmed: 12174734
J Affect Disord. 1989 Sep-Oct;17(2):197-8
pubmed: 2527895
Int Clin Psychopharmacol. 2007 Nov;22(6):338-47
pubmed: 17917552
J Affect Disord. 1993 Oct-Nov;29(2-3):85-96
pubmed: 8300981
Arch Gen Psychiatry. 2006 May;63(5):521-9
pubmed: 16651509
Cureus. 2021 Dec 5;13(12):e20180
pubmed: 35004004
Arch Gen Psychiatry. 1995 Jan;52(1):11-9
pubmed: 7811158
Core Evid. 2010 Jun 15;4:67-82
pubmed: 20694066
Am J Psychiatry. 2000 May;157(5):729-36
pubmed: 10784465
J Clin Psychiatry. 2007 Nov;68(11):1663-72
pubmed: 18052559
Arch Gen Psychiatry. 2009 Aug;66(8):848-56
pubmed: 19652124
Lancet Psychiatry. 2019 Nov;6(11):903-914
pubmed: 31543474
J Midlife Health. 2019 Jul-Sep;10(3):141-146
pubmed: 31579188
Clin Ther. 2009 Jun;31 Pt 1:1405-23
pubmed: 19698901
J Clin Psychiatry. 1991 May;52 Suppl:28-34
pubmed: 1903134
Lancet. 1997 May 17;349(9063):1436-42
pubmed: 9164317
Ann Intern Med. 2011 Dec 6;155(11):772-85
pubmed: 22147715
J Gen Intern Med. 1999 Sep;14(9):569-80
pubmed: 10491249
Arch Gen Psychiatry. 1994 Jan;51(1):8-19
pubmed: 8279933
Ethiop J Health Sci. 2013 Nov;23(3):283-8
pubmed: 24307828
J Clin Psychiatry. 2007 May;68(5):677-88
pubmed: 17503976